相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Application of the CRISPRi system to repress sepF expression in Mycobacterium smegmatis
Jing Xiao et al.
INFECTION GENETICS AND EVOLUTION (2019)
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis
Shu'an Wen et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study
Yu Pang et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Comparative genome analyses of mycobacteria give better insights into their evolution
Wei Yee Wee et al.
PLOS ONE (2017)
Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria
Isha Soni et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2016)
Mutations in Genes for the F420 Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in Spontaneous In Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis
Hana L. Haver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China
Zhijian Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system
Jing Wang et al.
NATURE IMMUNOLOGY (2015)
Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China
Zhijian Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
Susan E. Cellitti et al.
STRUCTURE (2012)
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs
Jotam G. Pasipanodya et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
Ann M. Ginsberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Mycobacterium tuberculosis Rv2224c modulates innate immune responses
Jyothi Rengarajan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Ramandeep Singh et al.
SCIENCE (2008)
Mycobacterium leprae is naturally resistant to PA-824
Ujjini H. Manjunatha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models
AJ Lenaerts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F420 and FO biosynthesis
KP Choi et al.
JOURNAL OF BACTERIOLOGY (2002)
Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium bovis BCG
KP Choi et al.
JOURNAL OF BACTERIOLOGY (2001)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
CK Stover et al.
NATURE (2000)
分享论文
